Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Kmak, Jamie A., Agarwal, Nikita, He, Yuting, Heilmann, Andreas M., Miller, Vincent A., Ross, Jeffrey S., Pal, Sumanta Kumar, Ali, Siraj M., Kilari, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204854/
https://www.ncbi.nlm.nih.gov/pubmed/32399016
http://dx.doi.org/10.1159/000506625
Descripción
Sumario:Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.

Ejemplares similares